Myriad to Launch Two Melanoma Tests Based on Newly Acquired Technology

In addition to a five-marker diagnostic test that the company plans to launch in the second half of 2011, Myriad is developing a second melanoma test that would gauge survival benefit.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.

Related Stories